A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma.

Trial Profile

A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Tremelimumab (Primary) ; Dacarbazine; Temozolomide
  • Indications Malignant melanoma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jan 2013 Results published in the Journal of Clinical Oncology.
    • 29 Sep 2009 Planned end date changed from Dec 2010 to Dec 2011 as reported by ClinicalTrials.gov.
    • 02 Apr 2008 Results are expected to be reported at ASCO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top